




Instance: composition-en-cb749713573713170146b8dc947ab1a6
InstanceOf: CompositionUvEpi
Title: "Composition for orgalutran Package Leaflet"
Description:  "Composition for orgalutran Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf50fe3ce231c6cccaa34cb0b7e6b103b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orgalutran"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Orgalutran is and what it is used for </li>
<li>What you need to know before you use Orgalutran </li>
<li>How to use Orgalutran </li>
<li>Possible side effects </li>
<li>How to store Orgalutran </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orgalutran is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orgalutran is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orgalutran contains the active substance ganirelix and belongs to a group of medicines called  anti-
gonadotrophin-releasing hormones  which act against the actions of the natural gonadotrophin 
releasing hormone (GnRH). GnRH regulates the release of gonadotrophins (luteinising hormone (LH) 
and follicle stimulating hormone (FSH)). Gonadotrophins play an important role in human fertility and 
reproduction. In women, FSH is needed for the growth and development of follicles in the ovaries. 
Follicles are small round sacs that contain the egg cells. LH is needed to release the mature egg cells 
from the follicles and ovaries (i.e. ovulation). Orgalutran inhibits the action of GnRH, resulting in 
suppression of the release of especially LH. </p>
<p>Orgalutran is used for </p>
<p>In women undergoing assisted reproduction techniques, including in vitro fertilisation (IVF) and other 
methods, occasionally ovulation may occur too early causing a significant reduction in the chance of 
getting pregnant. Orgalutran is used to prevent the premature LH surge that might cause such a 
premature release of egg cells. </p>
<p>In clinical studies Orgalutran was used with recombinant follicle stimulating hormone (FSH) or 
corifollitropin alfa, a follicle stimulant with a long duration of action. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orgalutran"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orgalutran"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Orgalutran </p>
<p>if you are allergic to ganirelix or any of the other ingredients of this medicine (listed in 
section 6); </p>
<p>if you are hypersensitive to gonadotrophin releasing hormone (GnRH) or a GnRH analogue; </p>
<p>if you have a moderate or severe kidney or liver disease; </p>
<p>if you are pregnant or breast-feeding. </p>
<p>Warnings and precautions 
Talk to your doctor, pharmacist or nurse before using Orgalutran </p>
<p>Allergic reactions </p>
<p>If you have an active allergic condition, please tell your doctor. Your doctor will decide, depending on 
the severity, if additional monitoring is required during treatment. Cases of allergic reactions have 
been reported, as early as with the first dose. </p>
<p>Allergic reactions, both generalised and local, including hives (urticaria), swelling of the face, lips 
tongue and/or throat that may cause difficulty in breathing and/or swallowing (angioedema and/or 
anaphylaxis) have been reported. (See also section 4.) If you have an allergic reaction, stop taking 
Orgalutran and seek immediate medical assistance. </p>
<p>Latex allergy </p>
<p>The needle cover contains dry natural rubber/latex which comes into contact with the needle and may 
cause allergic reactions. </p>
<p>Ovarian hyperstimulation syndrome (OHSS) </p>
<p>During or following hormonal stimulation of the ovaries, ovarian hyperstimulation syndrome may 
develop. This syndrome is related to the stimulation procedure with gonadotrophins. Please refer to the 
Package Leaflet of the gonadotrophin-containing medicine prescribed for you. </p>
<p>Multiple births or birth defects </p>
<p>The incidence of congenital malformations after assisted reproduction techniques may be slightly 
higher than after spontaneous conceptions. This slightly higher incidence is thought to be related to 
characteristics of the patients undergoing fertility treatment (e.g. age of the woman, sperm 
characteristics) and to the higher incidence of multiple gestations after assisted reproduction 
techniques. The incidence of congenital malformations after assisted reproduction techniques using 
Orgalutran is not different from that after using other GnRH analogues in the course of assisted 
reproduction techniques. </p>
<p>Pregnancy complications </p>
<p>There is a slightly increased risk of pregnancy outside of the uterus (an ectopic pregnancy) in women 
with damaged fallopian tubes. </p>
<p>Women weighing less than 50 kg or more than 90 kg </p>
<p>The efficacy and safety of Orgalutran has not been established in women weighing less than 50 kg or 
more than 90 kg. Ask your doctor for further information. </p>
<p>Children and adolescents<br />
There is no relevant use of Orgalutran in children or adolescents. </p>
<p>Other medicines and Orgalutran 
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. </p>
<p>Pregnancy, breast-feeding and fertility 
Orgalutran should be used during controlled ovarian stimulation for assisted reproduction techniques 
(ART). Do not use Orgalutran during pregnancy and breast-feeding. </p>
<p>Ask your doctor or pharmacist for advice before taking this medicine. </p>
<p>Driving and using machines 
The effects of Orgalutran on ability to drive and use machines have not been studied. </p>
<p>Orgalutran contains sodium 
Orgalutran contains less than 1 mmol sodium (23 mg) per injection,  that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orgalutran"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orgalutran"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. 
Orgalutran is used as part of the treatment for assisted reproduction techniques (ART) including 
in vitro fertilisation (IVF). 
Ovarian stimulation with follicle stimulating hormone (FSH) or corifollitropin may start at day 2 or 3 
of your period. Orgalutran (0.25 mg) should be injected just under the skin once daily, starting on day 
5 or day 6 of stimulation. Based on your ovarian response, your doctor may decide to start on another 
day.<br />
Orgalutran and FSH should be administered approximately at the same time. However, the 
preparations should not be mixed and different injection sites are to be used. </p>
<p>Daily treatment with Orgalutran should be continued up to the day that sufficient follicles of adequate 
size are present. Final maturation of the egg cells in the follicles can be induced by administering 
human chorionic gonadotrophin (hCG). The time between two Orgalutran injections as well as the 
time between the last Orgalutran injection and hCG injection should not exceed 30 hours, as otherwise 
a premature ovulation (i.e. release of egg cells) may occur. Therefore, when injecting Orgalutran in the 
morning treatment with Orgalutran should be continued throughout the gonadotrophin treatment 
period including the day of triggering ovulation. When injecting Orgalutran in the afternoon the last 
Orgalutran injection should be given in the afternoon prior to the day of triggering ovulation.  </p>
<p>Instructions for use </p>
<p>Injection site 
Orgalutran is supplied in pre-filled syringes and should be injected slowly, just under the skin, 
preferably in the upper leg. Inspect the solution before use. Do not use if the solution contains particles 
or is not clear. You may notice air bubble(s) in the pre-filled syringe. This is expected, and removal of 
the air bubble(s) is not needed. If you administer the injections yourself or have it done by your 
partner, follow the instructions below carefully. Do not mix Orgalutran with any other medicines. </p>
<p>Preparing the injection site 
Wash your hands thoroughly with soap and water. Swab the injection site with a disinfectant (for 
example alcohol) to remove any surface bacteria. Clean about 5 cm (two inches) around the point 
where the needle will go in and let the disinfectant dry for at least one minute before proceeding. </p>
<p>Inserting the needle 
Remove needle cover. Pinch up a large area of skin between finger and thumb. Insert the needle at the 
base of the pinched-up skin at an angle of 45  to the skin surface. Vary the injection site with each 
injection. </p>
<p>Checking the correct needle position 
Gently draw back the plunger to check if the needle is positioned correctly. Any blood drawn into the 
syringe means the needle tip has penetrated a blood vessel. If this happens, do not inject Orgalutran, 
but remove the syringe, cover the injection site with a swab containing disinfectant and apply pressure; 
bleeding should stop in a minute or two. Do not use this syringe and dispose of it properly. Start again 
with a new syringe. </p>
<p>Injecting the solution 
Once the needle has been correctly placed, depress the plunger slowly and steadily, so the solution is 
correctly injected and the skin tissues are not damaged. </p>
<p>Removing the syringe 
Pull the syringe out quickly and apply pressure to the site with a swab containing disinfectant. 
Use the pre-filled syringe only once. </p>
<p>If you use more Orgalutran than you should 
Contact your doctor. </p>
<p>If you forget to use Orgalutran 
If you realise that you forgot a dose, administer it as soon as possible. 
Do not inject a double dose to make up for a forgotten dose. 
If you are more than 6 hours late (so the time between two injections is longer than 30 hours) 
administer the dose as soon as possible and contact your doctor for further advice. </p>
<p>If you stop using Orgalutran 
Do not stop using Orgalutran unless advised to by your doctor, as this may affect the outcome of your 
treatment. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The chance of having a side effect is described by the following categories: </p>
<p>Very common: may affect more than 1 in 10 women </p>
<p>Local skin reactions at the site of injection (predominantly redness, with or without swelling). The 
local reaction normally disappears within 4 hours of administration.  </p>
<p>Uncommon: may affect up to 1 in 100 women </p>
<p>Headache </p>
<p>Nausea </p>
<p>Malaise  </p>
<p>Very rare: may affect up to 1 in 10,000 women </p>
<p>Allergic reactions have been observed, as early as with the first dose. 
* Rash 
* Facial swelling 
* Difficulty breathing (dyspnoea) 
* Swelling of face, lips, tongue, and/or throat that may cause difficulty in breathing and/or 
swallowing (angioedema and/or anaphylaxis) 
* Hives (urticaria) </p>
<p>Worsening of a pre-existing rash (eczema) has been reported in one subject after the first 
Orgalutran dose.  </p>
<p>In addition, side effects are reported which are known to occur with controlled ovarian 
hyperstimulation treatment (e.g. abdominal pain, ovarian hyperstimulation syndrome (OHSS), ectopic 
pregnancy (when the embryo develops outside the womb) and miscarriage (see the patient information 
leaflet of the FSH-containing preparation you are treated with)). </p>
<p>Reporting of side effects<br />
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orgalutran"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orgalutran"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on the label after 
 EXP . The expiry date refers to the last day of that month. </p>
<p>Do not freeze. 
Store in the original package, in order to protect from light. </p>
<p>Inspect the syringe before use. Use only syringes with clear, particle-free solutions and from 
undamaged containers. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Orgalutran contains 
- The active substance is ganirelix (0.25 mg in 0.5 mL solution). 
- The other ingredients are acetic acid, mannitol, water for injections. The pH (a measurement of 
the acidity) may have been adjusted with sodium hydroxide and acetic acid. </p>
<p>What Orgalutran looks like and contents of the pack 
Orgalutran is a clear and colourless aqueous solution for injection. The solution is ready for use and 
intended for subcutaneous administration. The needle cover contains dry natural rubber/latex 
which comes into contact with the needle. </p>
<p>Orgalutran is available in packs of 1 or 5 pre-filled syringes. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Marketing Authorisation Holder<br />
N.V. Organon 
Kloosterstraat 6 
5349 AB Oss 
The Netherlands </p>
<p>Manufacturer<br />
N.V. Organon, 
Kloosterstraat 6, 
Postbus 20, 
5340 BH Oss, 
The Netherlands. </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Organon Belgium 
T l/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Lietuva 
Organon Pharma B.V. Lithuania atstovyb<br />
Tel.: +370 52041dpoc.lithuania@organon.com </p>
<p>( . .)  . . -   <br />
 .: +359 2 806 3dpoc.bulgaria@organon.com </p>
<p>Luxembourg/Luxemburg 
Organon Belgium 
T l/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>esk  republika 
Organon Czech Republic s.r.o. 
Tel: +420 233 010 dpoc.czech@organon.com </p>
<p>Magyarorsz g 
Organon Hungary Kft. 
Tel.: +36 1 766 1dpoc.hungary@organon.com </p>
<p>Danmark 
Organon Denmark ApS<br />
Tlf: +45 4484 6info.denmark@organon.com </p>
<p>Malta 
Organon Pharma B.V., Cyprus branch 
Tel: +356 2277 8dpoc.cyprus@organon.com </p>
<p>Deutschland 
Organon Healthcare GmbH 
Tel.: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.germany@organon.com </p>
<p>Nederland 
N.V. Organon 
Tel: 00800 66550123 (+32 2 2418100) 
dpoc.benelux@organon.com </p>
<p>Eesti 
Organon Pharma B.V. Estonian RO 
Tel: +372 66 61 dpoc.estonia@organon.com  </p>
<p>Norge 
Organon Norway AS 
Tlf: +47 24 14 56 info.norway@organon.com </p>
<p>BIANE   . . 
 : +30 210 80091 Mailbox@vianex.gr </p>
<p>sterreich 
Organon Healthcare GmbH<br />
Tel: +49 (0) 89 2040022 dpoc.austria@organon.com 
Espa a 
Organon Salud, S.L. 
Tel: +34 91 591 12 organon_info@organon.com </p>
<p>Polska 
Organon Polska Sp. z o.o. 
Tel.: +48 22 105 50 organonpolska@organon.com </p>
<p>France 
Organon France 
T l: +33 (0) 1 57 77 32 Portugal 
Organon Portugal, Sociedade Unipessoal Lda. 
Tel: +351 218705geral_pt@organon.com </p>
<p>Hrvatska 
Organon Pharma d.o.o. 
Tel: +385 1 638 4dpoc.croatia@organon.com </p>
<p>Rom nia 
Organon Biosciences S.R.L. 
Tel: +40 21 527 29 dpoc.romania@organon.com<br />
Ireland 
Organon Pharma (Ireland) Limited 
Tel: +353 15828medinfo.ROI@organon.com </p>
<p>Slovenija 
Organon Pharma B.V., Oss, podru nica Ljubljana 
Tel: +386 1 300 10 dpoc.slovenia@organon.com </p>
<p>sland 
Vistor hf. 
S mi: + 354 535 7Slovensk  republika 
Organon Slovakia s. r. o. 
Tel: +421 2 44 88 98 dpoc.slovakia@organon.com </p>
<p>Italia 
Organon Italia S.r.l. 
Tel: +39 06 90259dpoc.italy@organon.com </p>
<p>Suomi/Finland 
Organon Finland Oy 
Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com </p>
<p>Organon Pharma B.V., Cyprus branch 
 : +357 22866dpoc.cyprus@organon.com </p>
<p>Sverige 
Organon Sweden AB 
Tel: +46 8 502 597 dpoc.sweden@organon.com </p>
<p>Latvija 
 rvalsts komersanta  Organon Pharma B.V.<br />
p rst vniec ba 
Tel: +371 66968dpoc.latvia@organon.com </p>
<p>United Kingdom (Northern Ireland) 
Organon Pharma (UK) Limited 
Tel: +44 (0) 208 159 3medicalinformationuk@organon.com  </p>
<p>This leaflet was last revised in {month YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-cb749713573713170146b8dc947ab1a6
InstanceOf: CompositionUvEpi
Title: "Composition for orgalutran Package Leaflet"
Description:  "Composition for orgalutran Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf50fe3ce231c6cccaa34cb0b7e6b103b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orgalutran"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at bruge Orgalutran 
3. Sådan skal du bruge Orgalutran 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orgalutran is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orgalutran is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orgalutran indeholder det aktive stof ganirelix og tilhører gruppen af medicin, der kaldes 
"antigonadotropin-frigivende hormoner", som virker imod det naturlige gonadotropinudskillende 
hormon GnRH. GnRH regulerer udskillelsen af gonadotropiner (luteiniserende hormon (LH) og 
follikelstimulerende hormon (FSH)). Gonadotropiner spiller en vigtig rolle i den menneskelige 
frugtbarhed og graviditet. Hos kvinder bruges FSH til vækst og udvikling af follikler i æggestokkene. 
Follikler er små runde poser, der indeholder ægceller. LH bruges til frigivelse af modnede ægceller fra 
folliklerne og æggestokkene (ægløsning). Orgalutran hæmmer virkningen af GnRH, resulterende i 
undertrykkelse af udskillelsen af specielt LH.  </p>
<p>Orgalutran anvendes til </p>
<p>Kvinder i medicinsk assisteret reproduktionsbehandling inklusive in vitro fertilisation (IVF) hvor der 
sommetider forekommer for tidlig ægløsning, hvilket forårsager en signifikant nedsættelse af chancen 
for at blive gravid. Orgalutran anvendes til at forhindre den tidlige bølge af LH, der kan forårsage en 
for tidlig ægløsning. </p>
<p>I kliniske studier blev Orgalutran anvendt sammen med rekombinant follikelstimulerende hormon 
(FSH) eller corifollitropin alfa, et follikelstimulerende stof med langtidsvirkning.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orgalutran"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orgalutran"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Brug ikke Orgalutran</h2>
<p>hvis du er allergisk over for ganirelix eller et af de øvrige indholdsstoffer i Orgalutran (angivet i 
punkt 6); 
- 
hvis du er overfølsom over for gonadotropinudskillende hormon (GnRH) eller en GnRH-
analog; 
- 
hvis du har en moderat til svær nyre- eller leverlidelse; 
- 
hvis du er gravid eller ammer. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du bruger Orgalutran. </p>
<p>Allergiske reaktioner </p>
<p>Hvis du har en aktiv allergisk tilstand, skal du fortælle det til din læge. Afhængig af sværhedsgraden 
vil lægen beslutte, om du skal overvåges særlig omhyggeligt under behandlingen. Der er rapporteret 
om allergiske reaktioner så tidligt som ved første dosis. </p>
<p>Der er rapporteret om allergiske reaktioner, både generaliserede og lokale, herunder nældefeber 
(urticaria), hævelse af ansigt, læber, tunge og/eller svælg, som kan medføre besvær med at trække 
vejret og/eller synke (angioødem og/eller anafylaksi) (se også punkt 4). Hvis du får en allergisk 
reaktion, skal du stoppe med at tage Orgalutran og straks søge lægehjælp.  </p>
<p>Latexallergi </p>
<p>Kanylens beskyttelseshætte indeholder tørt naturgummi/latex, som kommer i berøring med kanylen og 
kan fremkalde allergiske reaktioner. </p>
<p>Ovarieoverstimulations-syndrom (OHSS) </p>
<p>Under eller efter hormonel ovariestimulation kan der udvikles ovarieoverstimulations-syndrom. Dette 
relateres til gonadotropinstimulationsproceduren. Læs venligst indlægssedlen for den 
gonadotropinholdige medicin, der er ordineret til dig. </p>
<p>Flere fødsler eller medfødte misdannelser </p>
<p>Forekomsten af medfødte misdannelser efter medicinsk assisteret reproduktionsbehandling kan være 
en smule højere end ved naturlig undfangelse. Denne lettere forhøjede forekomst tænkes at skyldes 
egenskaber ved patienterne i reproduktionsbehandling (f.eks. kvindens alder, karakteristika ved 
mandens sæd) samt den højere forekomst af befrugtning af flere ægceller efter medicinsk assisteret 
reproduktionsbehandling. Forekomsten af medfødte misdannelser efter medicinsk assisteret 
reproduktionsbehandling med Orgalutran adskiller sig ikke fra den ved brug af andre GnRH-
præparater til brug i medicinsk assisteret reproduktionsbehandling.  </p>
<p>Komplikationer i forbindelse med graviditet </p>
<p>Der er en let øget risiko for graviditet uden for livmoderen (ektopisk graviditet) hos kvinder med 
beskadigede æggeledere. </p>
<p>Kvinder med en kropsvægt på under 50 kg eller over 90 kg </p>
<p>Orgalutrans sikkerhed og virkning er ikke påvist hos kvinder, som vejer mindre end 50 kg eller mere 
end 90 kg. Spørg din læge om yderligere information. </p>
<p>Børn og unge 
Brug ikke Orgalutran til børn eller unge. </p>
<p>Brug af anden medicin sammen med Orgalutran 
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt 
anden medicin eller planlægger at bruge anden medicin.  </p>
<p>Graviditet, amning og frugtbarhed 
Orgalutran anvendes under kontrolleret stimulation af æggestokkene i forbindelse med assisteret 
reproduktionsteknik, ART, (fertilitetsbehandling). Brug ikke Orgalutran under graviditet og amning. </p>
<p>Spørg din læge eller apotekspersonalet til råds, før du bruger dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed<br />
Der er ikke foretaget undersøgelser af indflydelsen på evnen til at føre bil eller betjene maskiner. </p>
<p>Orgalutran indeholder natrium 
Orgalutran indeholder mindre end 1 mmol (23 mg) natrium pr. injektion (indsprøjtning), dvs. det er i 
det væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orgalutran"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orgalutran"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Orgalutran bruges som en del af behandlingen med medicinsk assisteret reproduktionsteknik (ART) 
inklusive in vitro fertilisation (IVF).<br />
Ovariestimulation med follikelstimulerende hormon (FSH) eller corifollitropin kan starte på 
menstruationens 2. eller 3. dag. Orgalutran (0,25 mg) skal indsprøjtes lige under huden en gang 
dagligt, startende på dag 5 eller dag 6 efter stimulation. Afhængigt af reaktionen fra dine æggestokke 
kan din læge beslutte at starte behandlingen på en anden dag.<br />
Orgalutran må ikke blandes med FSH, men begge præparater skal gives næsten samtidig, men ikke 
samme sted.  </p>
<p>Den daglige behandling med Orgalutran skal fortsætte indtil den dag, hvor der findes et tilstrækkeligt 
antal follikler af passende størrelse. Sidste fase af modningen af ægcellerne i folliklerne fremskyndes 
ved indgivelse af humant chorion gonadotropin (hCG). Tidsrummet mellem to Orgalutran-injektioner 
og mellem den sidste Orgalutran-injektion og hCG-injektionen må ikke overstige 30 timer, idet der 
ellers kan forekomme for tidlig ægløsning (frigivelse af ægceller). Ved indgift om morgenen skal 
behandling med Orgalutran derfor fortsætte i hele gonadotropin behandlingsperioden, inkl. den dag 
ægløsningen starter. Ved indgift om eftermiddagen skal den sidste Orgalutran injektion tages om 
eftermiddagen før den dag, hvor ægløsningen starter. </p>
<p>Brugsvejledning </p>
<p>Injektionsstedet 
Orgalutran findes i fyldte sprøjter og skal indsprøjtes langsomt lige under huden, helst i låret. 
Kontroller opløsningen før anvendelse. Den må ikke anvendes, hvis den indeholder partikler eller er 
uklar. Du kan måske se luftbobler i den fyldte sprøjte. Dette er forventeligt, og det er ikke nødvendigt 
at fjerne luftboblerne. Hvis du selv eller din partner foretager de efterfølgende injektioner, skal du nøje 
følge instruktionerne nedenfor. Bland ikke Orgalutran med anden medicin.  </p>
<p>Klargøring af injektionsstedet 
Vask hænderne omhyggeligt med vand og sæbe. Injektionsstedet skal renses med et desinficerende 
middel (f.eks. sprit) for at fjerne bakterier på huden. Rens et område på ca. 5 cm rundt om 
injektionsstedet og lad desinfektionsmidlet tørre i mindst 1 minut, før du går videre.  </p>
<p>Indstik af kanylen 
Fjern beskyttelseshætten. Tag fat i en stor hudfold med tommel- og pegefinger. Stik kanylen ind i 
bunden af hudfolden i en vinkel på 45° på hudoverfladen. Du skal ændre injektionssted for hver 
injektion.  </p>
<p>Kontrol af kanylens korrekte position 
Træk forsigtigt stemplet tilbage for at sikre, at kanylen er placeret korrekt. Hvis der suges blod tilbage 
i sprøjten betyder det, at kanylens spids har gennemtrængt en blodåre. Skulle dette ske, skal du ikke 
indsprøjte Orgalutran, men trække sprøjten ud, dække injektionsstedet med et stykke vat med 
desinfektionsmiddel og presse ned på injektionsstedet; blødningen vil stoppe efter et par minutter. 
Anvend ikke sprøjten og kasser den efter anvisningerne. Du skal starte forfra med en ny sprøjte.  </p>
<p>Injektion af opløsningen 
Når kanylen er korrekt placeret, trykkes stemplet langsomt og roligt ned, så opløsningen indsprøjtes 
korrekt, og hudvævet ikke beskadiges.  </p>
<p>Fjernelse af sprøjten 
Træk sprøjten hurtigt ud og pres ned på injektionsstedet med et stykke vat med desinfektionsmiddel. 
Brug kun sprøjten en gang. </p>
<p>Hvis du har brugt for meget Orgalutran 
Kontakt din læge.  </p>
<p>Hvis du har glemt at bruge Orgalutran 
Hvis du opdager, at du har glemt at indsprøjte Orgalutran, skal det gøres snarest muligt.<br />
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. 
Hvis injektionen er givet mere end 6 timer for sent, så tidsrummet mellem to injektioner har oversteget 
30 timer, skal du tage injektionen snarest muligt samt kontakte din læge for at få yderligere 
rådgivning.  </p>
<p>Hvis du holder op med at bruge Orgalutran 
Du må ikke stoppe med Orgalutran, medmindre din læge råder dig til det, da dette kan påvirke 
resultatet af din behandling. </p>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Risikoen for at få en bivirkning er beskrevet ved hjælp af følgende kategorier: </p>
<p>Meget almindelige bivirkninger: kan berøre flere end 1 ud af 10 kvinder 
- Lokale hudreaktioner på injektionsstedet (især rødmen, med eller uden hævelse). Dette 
forsvinder normalt inden for 4 timer efter injektionen.  </p>
<p>Ikke almindelige bivirkninger: kan berøre op til 1 ud af 100 kvinder 
- Hovedpine<br />
- Kvalme<br />
- Utilpashed  </p>
<p>Meget sjældne bivirkninger: kan berøre op til 1 ud af 10.000 kvinder 
- Allergiske reaktioner er set så tidligt som ved første dosis. </p>
<ul>
<li>
<p>Udslæt </p>
</li>
<li>
<p>Opsvulmet ansigt </p>
</li>
<li>
<p>Vejrtrækningsbesvær (dyspnø) </p>
</li>
<li>
<p>Hævelse af ansigt, læber, tunge og/eller svælg som kan medføre besvær med at trække 
vejret og/eller synke (angioødem og/eller anafylaksi) </p>
</li>
<li>
<p>Nældefeber (urticaria) </p>
</li>
<li>Forværring af allerede eksisterende udslæt (eksem) er rapporteret hos en patient efter den første 
Orgalutran-dosis.  </li>
</ul>
<p>Herudover er der rapporteret andre bivirkninger, som er kendt for at optræde i forbindelse med den 
kontrollerede ovarieoverstimulationsbehandling (f.eks. mavesmerter, ovarieoverstimulations-syndrom 
(OHSS), graviditet uden for livmoderen (når fostret udvikler sig uden for livmoderen) og abort (læs 
indlægssedlen for det FSH-lægemiddel, du bliver behandlet med)).  </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orgalutran"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orgalutran"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.  </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på kartonen og etiketten efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned.  </p>
<p>Må ikke nedfryses.<br />
Opbevares i den originale yderpakning for at beskytte mod lys.  </p>
<p>Kontroller sprøjten før brug. Brug kun sprøjter med klar, partikelfri opløsning og i intakt emballage. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orgalutran indeholder:</p>
<ul>
<li>Aktivt stof: ganirelix (0,25 mg i 0,5 ml opløsning). </li>
<li>Øvrige indholdsstoffer: eddikesyre, mannitol, vand til injektionsvæsker. pH-værdien (et mål for 
surhedsgraden) kan være blevet justeret med natriumhydroxid og eddikesyre.  </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Orgalutran er en klar og farveløs vandig opløsning til injektion. Opløsningen er klar til brug og 
beregnet til injektion under huden. Kanylens beskyttelseshætte indeholder tørt naturgummi/latex, 
som kommer i berøring med kanylen. </p>
<p>Orgalutran findes i pakker med 1 eller 5 fyldte sprøjter.  </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen 
N.V. Organon 
Kloosterstraat 6 
5349 AB Oss 
Holland </p>
<p>Fremstiller<br />
N.V. Organon,<br />
Kloosterstraat 6,<br />
Postbus 20,<br />
5340 BH Oss,<br />
Holland.  </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Organon Belgium 
Tél/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Lietuva 
Organon Pharma B.V. Lithuania atstovybė 
Tel.: +370 52041dpoc.lithuania@organon.com </p>
<p>България 
Органон (И.А.) Б.В. - клон България 
Тел.: +359 2 806 3dpoc.bulgaria@organon.com </p>
<p>Luxembourg/Luxemburg 
Organon Belgium 
Tél/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Česká republika 
Organon Czech Republic s.r.o. 
Tel: +420 233 010 dpoc.czech@organon.com </p>
<p>Magyarország 
Organon Hungary Kft. 
Tel.: +36 1 766 1dpoc.hungary@organon.com </p>
<p>Danmark 
Organon Denmark ApS<br />
Tlf: +45 4484 6info.denmark@organon.com </p>
<p>Malta 
Organon Pharma B.V., Cyprus branch 
Tel: +356 2277 8dpoc.cyprus@organon.com </p>
<p>Deutschland 
Organon Healthcare GmbH 
Tel.: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.germany@organon.com </p>
<p>Nederland 
N.V. Organon 
Tel: 00800 66550123 (+32 2 2418100) 
dpoc.benelux@organon.com </p>
<p>Eesti 
Organon Pharma B.V. Estonian RO 
Tel: +372 66 61 dpoc.estonia@organon.com  </p>
<p>Norge 
Organon Norway AS 
Tlf: +47 24 14 56 info.norway@organon.com </p>
<p>Ελλάδα 
BIANEΞ Α.Ε. 
Τηλ: +30 210 80091 Mailbox@vianex.gr </p>
<p>Österreich 
Organon Healthcare GmbH<br />
Tel: +49 (0) 89 2040022 dpoc.austria@organon.com 
España 
Organon Salud, S.L. 
Tel: +34 91 591 12 organon_info@organon.com </p>
<p>Polska 
Organon Polska Sp. z o.o. 
Tel.: +48 22 105 50 organonpolska@organon.com </p>
<p>France 
Organon France 
Tél: +33 (0) 1 57 77 32<br />
Portugal 
Organon Portugal, Sociedade Unipessoal Lda. 
Tel: +351 218705geral_pt@organon.com </p>
<p>Hrvatska 
Organon Pharma d.o.o. 
Tel: +385 1 638 4dpoc.croatia@organon.com </p>
<p>România 
Organon Biosciences S.R.L. 
Tel: +40 21 527 29 dpoc.romania@organon.com<br />
Ireland 
Organon Pharma (Ireland) Limited 
Tel: +353 15828medinfo.ROI@organon.com </p>
<p>Slovenija 
Organon Pharma B.V., Oss, podružnica Ljubljana 
Tel: +386 1 300 10 dpoc.slovenia@organon.com 
Ísland 
Vistor hf. 
Sími: + 354 535 7 
Slovenská republika 
Organon Slovakia s. r. o. 
Tel: +421 2 44 88 98 dpoc.slovakia@organon.com </p>
<p>Italia 
Organon Italia S.r.l. 
Tel: +39 06 90259dpoc.italy@organon.com </p>
<p>Suomi/Finland 
Organon Finland Oy 
Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com </p>
<p>Κύπρος 
Organon Pharma B.V., Cyprus branch 
Τηλ: +357 22866dpoc.cyprus@organon.com </p>
<p>Sverige 
Organon Sweden AB 
Tel: +46 8 502 597 dpoc.sweden@organon.com </p>
<p>Latvija 
Ārvalsts komersanta “Organon Pharma B.V." 
pārstāvniecība 
Tel: +371 66968dpoc.latvia@organon.com </p>
<p>United Kingdom (Northern Ireland) 
Organon Pharma (UK) Limited 
Tel: +44 (0) 208 159 3medicalinformationuk@organon.com  </p>
<p>Denne indlægsseddel blev senest ændret {måned ÅÅÅÅ}  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-cb749713573713170146b8dc947ab1a6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orgalutran Package Leaflet for language en"
Description: "ePI document Bundle for orgalutran Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-cb749713573713170146b8dc947ab1a6"
* entry[0].resource = composition-en-cb749713573713170146b8dc947ab1a6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpcb749713573713170146b8dc947ab1a6"
* entry[=].resource = mpcb749713573713170146b8dc947ab1a6
                            
                    
Instance: bundlepackageleaflet-da-cb749713573713170146b8dc947ab1a6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orgalutran Package Leaflet for language da"
Description: "ePI document Bundle for orgalutran Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-cb749713573713170146b8dc947ab1a6"
* entry[0].resource = composition-da-cb749713573713170146b8dc947ab1a6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpcb749713573713170146b8dc947ab1a6"
* entry[=].resource = mpcb749713573713170146b8dc947ab1a6
                            
                    



Instance: mpcb749713573713170146b8dc947ab1a6
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product orgalutran"
Description: "orgalutran"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/00/130/001, 1 pre-filled syringe"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Orgalutran is indicated for the prevention of premature luteinising hormone (LH) surges in women"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "orgalutran"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: cb749713573713170146b8dc947ab1a6ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "orgalutran"

* status = #current
* mode = #working

* title = "List of all ePIs associated with orgalutran"

* subject = Reference(mpf50fe3ce231c6cccaa34cb0b7e6b103b)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#orgalutran "orgalutran"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-cb749713573713170146b8dc947ab1a6) // orgalutran en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-cb749713573713170146b8dc947ab1a6) // orgalutran da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-cb749713573713170146b8dc947ab1a6
InstanceOf: List

* insert cb749713573713170146b8dc947ab1a6ListRuleset
    